PLRX · NASDAQ
Pliant Therapeutics (PLRX) Stock Price & Fundamentals
Pliant Therapeutics (PLRX) closed at $746.48 on Oct 9, 2026, down 0.56% from the previous close of $750.65.
Share price, past year
1Y +21.39%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $746.48 |
| Sep 30, 2026 | $746.49 |
| Aug 31, 2026 | $739.13 |
| Jul 31, 2026 | $732.99 |
| Jun 30, 2026 | $725.81 |
| May 29, 2026 | $704.76 |
| Apr 30, 2026 | $655.46 |
| Mar 31, 2026 | $673.62 |
| Feb 27, 2026 | $684.68 |
| Jan 30, 2026 | $658.43 |
| Dec 31, 2025 | $670.10 |
| Nov 28, 2025 | $648.11 |
| Oct 31, 2025 | $647.28 |
Key statistics
- Market cap
- $46.22B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.48
- Revenue (TTM)
- —
- Net income (TTM)
- −$92.29M
- Shares outstanding
- 61.9M
- Dividend yield
- —
- 52-week range
- $614.47 – $794.44
Pliant Therapeutics's market cap is $46.22B, based on a share price of $746.48 and 61.9M shares outstanding as of Jun 30, 2026.
Financials
Pliant Therapeutics reported revenue of $0.00 for fiscal 2025.
Pliant Therapeutics reported a net loss of $149.34M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | — | −$149.34M | — | −$2.43 | −$128.71M |
| FY2024ended Dec 31, 2024 | $0.00 | −100.0% | −$210.30M | — | −$3.47 | −$159.35M |
| FY2023ended Dec 31, 2023 | $1.58M | −83.7% | −$161.34M | −10,211.1% | −$2.75 | −$117.28M |
| FY2022ended Dec 31, 2022 | $9.69M | +27.9% | −$123.32M | −1,273.3% | −$2.94 | −$96.39M |
| FY2021ended Dec 31, 2021 | $7.57M | −81.9% | −$97.26M | −1,284.5% | −$2.71 | −$77.40M |
| FY2020ended Dec 31, 2020 | $41.82M | −26.7% | −$41.53M | −99.3% | −$1.95 | −$38.80M |
| FY2019ended Dec 31, 2019 | $57.05M | — | −$631.00K | −1.1% | −$4.22 | −$3.71M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$49.73M | −$0.82 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$57.76M | −$0.95 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
| Q1 FY2024ended Mar 31, 2024 | $0.00 | — | — |
| Q4 FY2023ended Dec 31, 2023 | $0.00 | — | — |
| Q3 FY2023ended Sep 30, 2023 | $0.00 | — | — |
| Q2 FY2023ended Jun 30, 2023 | $248.00K | — | — |
| Q1 FY2023ended Mar 31, 2023 | $1.33M | — | — |
Company profile
- Name
- Pliant Therapeutics, Inc.
- Ticker
- PLRX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 331 Oyster Point Boulevard, South San Francisco, CA 94080
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001746473
Recent SEC filings
- Aug 11, 2026
- Aug 11, 2026
- Jul 13, 2026
- Jun 11, 2026
- May 11, 2026
- May 11, 2026
- Apr 17, 2026
- Mar 30, 2026
Frequently asked questions
What is Pliant Therapeutics's stock price?
Pliant Therapeutics (PLRX) closed at $746.48 on Oct 9, 2026, down 0.56% from the previous close of $750.65.
What is Pliant Therapeutics's market cap?
Pliant Therapeutics's market cap is $46.22B, based on a share price of $746.48 and 61.9M shares outstanding as of Jun 30, 2026.
How much revenue does Pliant Therapeutics make?
Pliant Therapeutics reported revenue of $0.00 for fiscal 2025.
Does Pliant Therapeutics pay a dividend?
Yes. Pliant Therapeutics declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from Pliant Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures